StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.75+0.04 (+1.08%)

Close on Nov 17, 2026Market cap $286.12MP/E –Yield –

Fulcrum Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Fulcrum Therapeutics

Fulcrum Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Fulcrum Therapeutics figures

See a number that looks wrong?